<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336139</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1309</org_study_id>
    <nct_id>NCT02336139</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use</brief_title>
  <acronym>SIMPLIFY</acronym>
  <official_title>A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post end of
      treatment (SVR12) following sofosbuvir/GS-5816 therapy for 12 weeks in people with chronic
      HCV infection and recent injection drug use.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response (SVR12)</measure>
    <time_frame>Week 24</time_frame>
    <description>To evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following sofosbuvir (SOF)/GS-5816 therapy for 12 weeks in people with chronic HCV infection and recent injection drug use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>To evaluate the proportion of patients adherent to therapy (both on-treatment adherence and treatment discontinuation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of adherence on therapy (association between adherence and response to treatment )</measure>
    <time_frame>early (0-3 weeks), mid (4-7 weeks) and late (8-11 weeks) during therapy</time_frame>
    <description>To evaluate the association between adherence and response to treatment [including an evaluation of the impact of early (0-3 weeks), mid (4-7 weeks) and late (8-11 weeks) missed doses on response to therapy]; Adehernce will be measure via a self report quesitonanire and pill counts via return of the weeekly blister packs. The impact of the number and timing of missed pills will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with on-treatment adherence</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>To evaluate factors associated with on-treatment adherence &gt;90% and treatment discontinuation. Demographic and behavioural factors will be examined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (ETR) (proportion of participants with undetectable HCV RNA at the end of treatment (ETR)</measure>
    <time_frame>Week 12</time_frame>
    <description>To evaluate the proportion of participants with undetectable HCV RNA at the end of treatment (ETR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (number and type of adverse events and serious adverse events)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To evaluate the number and type of adverse events and serious adverse events on treament and for 12 weeks post end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug use</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>To evaluate the change in drug use during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mental health</measure>
    <time_frame>Basleine to Week 12</time_frame>
    <description>To evaluate the change in mental health during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>To evaluate the change in health-related quality of life during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of mixed infection on treatment response</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To evaluate the rate of mixed HCV infection at baseline and among those with treatment non-response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection Rate</measure>
    <time_frame>Week 108</time_frame>
    <description>To evaluate the rate of HCV reinfection during and up to two years following treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunovirological factors associated with treatment clearance</measure>
    <time_frame>Week 24</time_frame>
    <description>To evaluate immunovirological factors associated with treatment clearance. We will evaluate cytokines and chemokines (e.g. interferon inducible protein 10), T-cell responses, viral evolution and genetic markers (e.g. inteferon lambda 4) that are potentially associated with treatment induced clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility of Dried Blood Spot (DBS) (method for monitoring HCV including treatment response)</measure>
    <time_frame>Week 108</time_frame>
    <description>To evaluate the utility of dried blood spot (DBS) as a simple method for monitoring HCV including treatment response. HCV RNA will be measured from DBS samples and then compared to HCV RNA levels measured using standard methods (EDTA Plasma samples and Roche Taqman)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir (SOF)/GS-5816</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir (SOF)/GS-5816</intervention_name>
    <description>12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose</description>
    <arm_group_label>Sofosbuvir (SOF)/GS-5816</arm_group_label>
    <other_name>SOF/GS-5816</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants have voluntarily signed the informed consent form.

          2. 18 years of age or older.

          3. Chronic HCV infection as defined by anti-HCV antibody or HCV RNA detection for greater
             than 6 months.

          4. HCV RNA plasma ≥ 1000 IU/ml at Screening.

          5. HCV genotypes 1-6.

          6. Recent injecting drug use (previous 6 months).

          7. Compensated liver disease.

          8. Participants with Fibroscan &gt;12 KPa or AFP &gt;50 ng/mL must have an abdominal ultrasound
             or CT scan without evidence of hepatocellular carcinoma within 2 months prior to
             screening.

          9. Negative pregnancy test at baseline (females of childbearing potential only).

         10. All fertile males and females must be using effective contraception during treatment
             and during the 30 days after treatment end.

        Exclusion Criteria:

          1. History of any of the following:

               1. Clinically significant illness (other than HCV) or any other major medical
                  disorder that may interfere with the participant treatment, assessment or
                  compliance with the protocol; participants currently under evaluation for a
                  potentially clinically significant illness (other than HCV) are also excluded.

               2. Clinical hepatic decompensation (i.e. ascites, encephalopathy or variceal
                  haemorrhage)

               3. Solid organ transplant

               4. Malignancy within 5 years prior to screening, with exception of specific cancers
                  that may have been cured by surgical resection (basal cell skin cancer, etc.).
                  Subjects under evaluation for possible malignancy are also excluded.

               5. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

          2. Screening ECG with clinically significant abnormalities

          3. Any of the following lab parameters at screening:

               1. ALT &gt; 10 x ULN

               2. AST &gt; 10 x ULN

               3. Direct bilirubin &gt; 1.5 x ULN

               4. Platelets &lt; 50,0000/μL

               5. HbA1c &gt; 8.5%

               6. Creatinine clearance (CLcr) &lt; 60 mL/min

               7. Haemoglobin &lt; 11 g/dL for females ; &lt; 12 g/dL for males

               8. Albumin &lt; 30g/L

               9. INR &gt; 1.5 ULN unless subject has known haemophilia or is stable on an
                  anticoagulant regimen affecting INR

          4. Pregnant or nursing female.

          5. HIV infection or HBV infection (HBcAb and HBsAg positive)

          6. Use of prohibited concomitant medications as described in section 5.2

          7. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone
             equivalent &gt; 10 mg/day)

          8. Known hypersensitivity to GS-5816, sofosbuvir (SOF) or formulation excipients.

          9. Therapy with any anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of
             study drug.

         10. Any investigational drug ≤6 weeks prior to the first dose of study drug.

         11. Previous therapy with sofosbuvir (SOF) or an NS5A inhibitor prior to the first dose of
             study drug.

         12. Ongoing severe psychiatric disease as judged by the treating physician.

         13. Frequent injecting drug use that is judged by the treating physician to compromise
             treatment safety.

         14. Inability or unwillingness to provide informed consent or abide by the requirements of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Dore, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kirby Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

